CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Word spread quickly online about the change after Caremark ... s employer clients paid for obesity drugs by 10 to 15 percent compared with the previous year. “CVS Caremark was able to do what ...

This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

Omada Health, a virtual chronic care provider, filed to go public Friday, marking the second digital health company making ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

They’re among the hottest-selling drugs in the country. But in Massachusetts, as elsewhere in the country, the people who would benefit most from these drugs may not be getting them, according ...